Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
14 03 2019
Historique:
received: 02 09 2018
accepted: 18 12 2018
pubmed: 4 1 2019
medline: 9 11 2019
entrez: 4 1 2019
Statut: ppublish

Résumé

Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with ≥5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage,

Identifiants

pubmed: 30602617
pii: S0006-4971(20)42705-3
doi: 10.1182/blood-2018-09-873083
pmc: PMC6509568
doi:

Substances chimiques

Biomarkers, Tumor 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1205-1216

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Genes Chromosomes Cancer. 2009 Oct;48(10):843-53
pubmed: 19582829
Blood. 2011 Mar 17;117(11):3016-24
pubmed: 21245487
Blood. 2017 Jun 22;129(25):3362-3370
pubmed: 28473407
Genes Chromosomes Cancer. 2016 May;55(5):480-91
pubmed: 26774012
Int J Cancer. 2016 Oct 15;139(8):1759-63
pubmed: 27270786
Blood. 2017 Jun 29;129(26):3495-3498
pubmed: 28446433
Blood. 1980 Oct;56(4):640-7
pubmed: 6968231
Cancer Genet. 2011 Feb;204(2):77-83
pubmed: 21494579
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
N Engl J Med. 2005 Feb 24;352(8):804-15
pubmed: 15728813
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155
pubmed: 27913474
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Br J Haematol. 2007 Jul;138(2):217-20
pubmed: 17593029
Leuk Lymphoma. 2013 May;54(5):986-95
pubmed: 22994157
Blood. 2006 Nov 1;108(9):3152-60
pubmed: 16840733
Blood. 2007 Jun 1;109(11):4679-85
pubmed: 17299097
Br J Haematol. 2018 Aug;182(3):412-417
pubmed: 29808933
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Cancer Genet Cytogenet. 2010 Dec;203(2):161-8
pubmed: 21156228
N Engl J Med. 1990 Sep 13;323(11):720-4
pubmed: 2201915
Leukemia. 2014 Mar;28(3):710-3
pubmed: 24217197
Leuk Lymphoma. 2017 Jul;58(7):1548-1560
pubmed: 27808579
Br J Haematol. 2012 Oct;159(1):82-7
pubmed: 22831395
Methods Mol Biol. 2011;730:119-30
pubmed: 21431638
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Haematologica. 2018 Sep;103(9):1511-1517
pubmed: 29880613
Leukemia. 2007 Dec;21(12):2442-51
pubmed: 17805327
Am J Hematol. 2016 Mar;91(3):330-40
pubmed: 26690614
J Intern Med. 2016 Apr;279(4):347-57
pubmed: 26709197
Haematologica. 2014 Jun;99(6):1088-94
pubmed: 24658818
Blood. 2012 May 10;119(19):4467-75
pubmed: 22415752
Haematologica. 2012 Mar;97(3):437-41
pubmed: 22207691
Cancer. 2015 Oct 15;121(20):3612-21
pubmed: 26193999
Br J Haematol. 2018 Apr;181(2):229-233
pubmed: 29611195
Am J Hematol. 2016 Oct;91(10):978-83
pubmed: 27341486
Cancer Genet Cytogenet. 1990 Apr;45(2):143-60
pubmed: 2180558
Blood. 2016 Jul 21;128(3):395-404
pubmed: 27226433
Ann Oncol. 2017 May 1;28(5):1050-1056
pubmed: 28453705
Hematol Oncol. 2017 Dec;35(4):664-670
pubmed: 27678008
Ann Oncol. 2010 Oct;21 Suppl 7:vii154-64
pubmed: 20943609
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2016 Apr 7;127(14):1752-60
pubmed: 26841802
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2013 Feb;27(2):512-4
pubmed: 23138133
Eur J Haematol. 2014 Feb;92(2):91-101
pubmed: 24138550
Haematologica. 2016 Jul;101(7):e299-302
pubmed: 27102498
Oncotarget. 2017 Apr 21;8(33):54297-54303
pubmed: 28903342
Oncotarget. 2016 Dec 6;7(49):80916-80924
pubmed: 27821812
Am J Hematol. 2014 Mar;89(3):249-55
pubmed: 24166834
Blood. 2014 Apr 3;123(14):2139-47
pubmed: 24501221
Blood. 2011 Sep 15;118(11):3051-61
pubmed: 21795749
Haematologica. 2018 Apr;103(4):e158-e161
pubmed: 29269523
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
Blood. 2016 Apr 28;127(17):2122-30
pubmed: 26837699
Blood. 2012 Mar 8;119(10):2310-3
pubmed: 22246039
Acta Haematol. 2017;138(1):65-66
pubmed: 28743106
Cancer Genet Cytogenet. 1997 Mar;94(1):27-35
pubmed: 9078288
Blood. 2018 Apr 19;131(16):1820-1832
pubmed: 29358183
Ann Biol Clin (Paris). 2016 Oct 1;74(5):561-567
pubmed: 27628190
Genes Chromosomes Cancer. 2010 Sep;49(9):851-9
pubmed: 20552631
Leukemia. 2012 Jan;26(1):170-2
pubmed: 21788947
Leukemia. 2018 May;32(5):1070-1080
pubmed: 29467486
Blood. 2015 Aug 20;126(8):1043-4
pubmed: 26294719
Haematologica. 2019 Feb;104(2):360-369
pubmed: 30262567
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
Blood. 2000 Dec 15;96(13):4075-83
pubmed: 11110676
Biomed Res Int. 2014;2014:435983
pubmed: 24967369
Haematologica. 2007 Sep;92(9):1242-5
pubmed: 17666364
Leukemia. 2010 Jan;24(1):211-5
pubmed: 19741724
Lancet Haematol. 2014 Nov;1(2):e74-84
pubmed: 27030157
Cancer Genet. 2017 Jan;210:1-8
pubmed: 28212806
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713

Auteurs

Panagiotis Baliakas (P)

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Sabine Jeromin (S)

MLL Munich Leukemia Laboratory, Munich, Germany.

Michalis Iskas (M)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Anna Puiggros (A)

Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain.
Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

Karla Plevova (K)

Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Florence Nguyen-Khac (F)

Hematology Department and Sorbonne University, Hopital Pitie-Salpetriere, INSERM U1138, Paris, France.

Zadie Davis (Z)

Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.

Gian Matteo Rigolin (GM)

Hematology Section, St. Anna University Hospital, Ferrara, Italy.

Andrea Visentin (A)

Hematology Division, Department of Medicine, University of Padua, Padua, Italy.

Aliki Xochelli (A)

Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.

Julio Delgado (J)

Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.

Fanny Baran-Marszak (F)

Laboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France.

Evangelia Stalika (E)

Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.

Pau Abrisqueta (P)

Servei d'Hematología, Hospital Vall d'Hebron, Barcelona, Spain.

Kristina Durechova (K)

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

George Papaioannou (G)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Virginie Eclache (V)

Laboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France.

Maria Dimou (M)

Hematology Section, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.

Theodoros Iliakis (T)

Hematology Section, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.

Rosa Collado (R)

Servicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain.

Michael Doubek (M)

Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

M Jose Calasanz (MJ)

Servicio de Genética Citogenética, Departamento de Genética, Universidad de Navarra, Pamplona, Spain.

Neus Ruiz-Xiville (N)

Servei Laboratori Hematologia, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), Universitat Autònoma de Barcelona, Badalona, Spain.

Carolina Moreno (C)

Servei d'Hematologia, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.

Marie Jarosova (M)

Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Alexander C Leeksma (AC)

Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
Department of Experimental Immunology, Cancer Center Amsterdam and Infection and Immunity Institute of Amsterdam, Amsterdam, The Netherlands.

Panayiotis Panayiotidis (P)

Hematology Section, First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, Laikon University Hospital, Athens, Greece.

Helena Podgornik (H)

Department of Hematology, University Medical Centre Ljubljana, Ljubljana, Slovenia; and.

Florence Cymbalista (F)

Laboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France.

Achilles Anagnostopoulos (A)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Livio Trentin (L)

Hematology Division, Department of Medicine, University of Padua, Padua, Italy.

Niki Stavroyianni (N)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

Fred Davi (F)

Hematology Department and Sorbonne University, Hopital Pitie-Salpetriere, INSERM U1138, Paris, France.

Paolo Ghia (P)

Strategic Research Program in CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Università Vita-Salute San Raffaele, Milan, Italy.

Arnon P Kater (AP)

Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
Department of Experimental Immunology, Cancer Center Amsterdam and Infection and Immunity Institute of Amsterdam, Amsterdam, The Netherlands.

Antonio Cuneo (A)

Hematology Section, St. Anna University Hospital, Ferrara, Italy.

Sarka Pospisilova (S)

Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Blanca Espinet (B)

Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain.
Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

Anastasia Athanasiadou (A)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.

David Oscier (D)

Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.

Claudia Haferlach (C)

MLL Munich Leukemia Laboratory, Munich, Germany.

Kostas Stamatopoulos (K)

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH